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Objectives:  This  study  aimed  to  test  the hypothesis  that the  range  of  24-h  total  heart  beats  (24 h-tHB)
correlates  with  cardiac  outcomes  (cardiac  death  and  incidence  of hospitalization  with  heart  failure)  in
patients  with  permanent  atrial  ﬁbrillation  (AF).
Methods and results:  We  divided  252  consecutive  outpatients  with  permanent  AF  into  4  groups  accord-
ing  to their  24 h-tHB  and  examined  clinical  outcomes.  Initial  24 h-tHB  at  enrollment  was signiﬁcantly
associated  with  patient  characteristics  including  age,  sex,  presence  of structural  heart  diseases,  and  left
ventricular  ejection  fraction  (EF).  The  cumulative  incidence  of heart  failure  was  high in the  lowest  24  h-
tHB  group  compared  with  other  groups  and  signiﬁcantly  different  from  the  highest  one  (23.9% vs. 7.2%eart failure at  5 years,  p  = 0.0074).  Multivariate  analysis  showed  that  24 h-tHB  < 100,000  was associated  with  cardiac
events  [hazard  ratio,  2.45;  95%  conﬁdence  interval  (CI),  1.09–5.49;  p  = 0.03),  along  with  structural  heart
disease  (hazard  ratio,  9.81;  95%  CI, 3.34–28.83;  p =  0.0001)  and  EF (hazard  ratio,  0.97;  95% CI,  0.94–0.99;
p  =  0.002).
Conclusions:  Surprisingly,  low  but not  high  heart  rate  was  signiﬁcantly  associated  with  higher incidence  of
heart failure  in Japanese  patients.  This  ﬁnding  should  be further  evaluated  in  future  prospective  studies.
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Previous clinical trials have demonstrated that patients with
trial ﬁbrillation (AF) can be effectively managed with heart rate
ontrol and anticoagulation [1–6]. In AF patients with rapid ven-
ricular response, reducing the ventricular contraction rate to an
ppropriate level is an important aspect of rate control, based on
he consideration that loss of atrial contraction may  decrease dias-
olic ventricular ﬁlling, especially in the presence of a structural
eart disease [7–11].
To date, rather strict control levels of heart rate in AF patients
ave been indicated by several guidelines, as recommended fol-
owing the AFFIRM (Atrial Fibrillation Investigation of Rhythm
anagement) and RACE (RAte Control vs. Electrical cardioversion)
∗ Corresponding author at: The Cardiology Department, Faculty of Medicine, Uni-
ersity of Juntendo, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan.
el.: +81 3 3813 3111; fax: +81 3 5689 0627.
E-mail address: khirano@juntendo.ac.jp (K. Hirano).
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
oi:10.1016/j.jjcc.2012.02.002anese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
studies [1,5]. However, a recent RACE II (RAte Control Efﬁcacy in
permanent atrial ﬁbrillation II) study demonstrated that a more
lenient control level is acceptable, suggesting the need for further
study of the adequate level of heart rate control in AF patients [12].
In Japan, these issues have not been fully discussed [13], and
adequate control levels of heart rate in Japanese AF patients remain
unclear. To address this question, the present study analyzed the
relationship between the total heartbeats in Holter recordings and
the prognosis of Japanese permanent AF patients.
Methods
Patients
From April 1999 to March 2002, 285 outpatients with perma-
nent AF underwent 24-h Holter recordings at our hospital. We
excluded 33 patients for the following reasons: (1) 20 patients
were excluded at enrollment because of a history of acute coronary
syndrome or myocardial infarction within the last 2 months, or a
history of implantation of any pacing devices; and (2) 13 patients,
vier Ltd. All rights reserved.
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eFig. 1. Flow chart for classiﬁcation of study participants. N, numb
ncluding those who underwent catheter ablation, were excluded
t the end of the follow-up period because their cardiac rhythm
ad switched to sinus rhythm or atrial ﬂutter during the follow-up
eriod. The remaining 252 patients were included in the analysis
Fig. 1).
4-h total heart beat measurements at enrollment and follow-up
Initial 24-h total heart beat (24 h-tHB) measurements were
ade at the time of enrollment in the study. In addition, at enroll-
ent all clinical records in our hospital were reviewed, including
istory of diseases, physical examination reports, laboratory data,
nd information regarding medications. Prognostic data were also
btained from the clinical records between April 1999 and March
007. Holter recordings were monitored using Marquette-K, SEER,
nd SEER-MC 24-h Holter monitoring systems.
To identify alterations in 24 h-tHB, we also obtained follow-
p data from measurements of 24 h-tHB by 673 Holter recordings
uring the observation period, excluding those with the follow-
ng characteristics: (1) hospitalization for surgery, heart failure,
r other cardiovascular events within 3 months of recording; (2)
ecordings of poor quality or with an insufﬁcient recording time
less than 23.5 h); and (3) switching of heart rhythm to sinus
hythm or atrial ﬂutter during the recording time.
ndpoints
We deﬁned cardiac events as the endpoint of the present study;
hese events included cardiac death (heart failure and sudden death
ith ventricular arrhythmia) and hospitalization with heart fail-
re. We  also counted other adverse events, including implantation
f pacemaker or implantable cardioverter deﬁbrillator (ICD), ven-
ricular tachyarrhythmia, hospitalization with angina pectoris or
cute coronary syndrome, stroke or transient ischemia attack, and
ll-cause mortality, although these were not included in the further
tatistical analyses.
tatistical analyses
Patients were divided into 4 groups according to the quartiles
f baseline 24 h-tHB (Fig. 1). (Baseline recordings are those made
n enrollment.) First, baseline descriptive statistics were calcu-
ated and are presented as mean ± SD for continuous variables and
ounts with percentages for categorical variables. Differences of
ontinuous and categorical variables between the 4 groups were
valuated by one-way ANOVA and Chi-square test, respectively.atients; 24 h-tHB, 24-h total heart beat; and AF, atrial ﬁbrillation.
Second, to clarify trends in 24 h-tHB, annual average values of 24 h-
tHB were calculated separately in each group. Third, cumulative
event-free survival rates for cardiac events were estimated by the
Kaplan–Meier method and differences among the 4 groups were
compared using the log-rank test. Finally, to evaluate the indepen-
dent effect of 24 h-tHB on the cardiac events, the Cox proportional
hazard regression model was employed. The ﬁnal multivariate
model included 24 h-tHB < 100,000 (an alternative value of the
quartile group with the highest incidence of cardiac events) and
other baseline covariates that showed signiﬁcant univariate rela-
tionships with cardiac events.
These analyses were performed using the SPSS statistical
software (version 19.0; SPSS Inc., Chicago, IL, USA). Statistical sig-
niﬁcance was set at a 2-sided p-value of <0.05.
Results
Patient characteristics
The study subjects consisted of 252 consecutive outpatients
with permanent AF (age 64 ± 10 years, 63 women) who underwent
24 h-tHB at the Cardiovascular Institute Hospital between April
1999 and March 2002. Baseline characteristics of the study patients
are presented in Table 1. Among the 4 quartiles, the average age,
prevalence of structural heart diseases (mostly valvular heart dis-
ease), and mean value of left ventricular ejection fraction (EF) were
the highest in the lowest 24 h-tHB quartile (1st quartile). The per-
centages of the patients using rate control medication at enrollment
in the 4 quartiles were 56%, 51%, 62%, and 57%, respectively.
Drug treatment
Drugs used during the initial 2 years are shown in Table 2. The
percentages of patients in whom initial 24 h-tHB was  recorded
before rate control in the 4 quartiles were 2%, 6%, 5%, and 24%,
respectively. The prescription rates for drugs for rate control,
including digoxin, calcium-channel blockers, and beta-blockers
were similar between the 4 groups. However, the prescription
rates for angiotensin-converting enzyme inhibitors or angiotensin
II receptor blockers and warfarin signiﬁcantly increased from the
4th (highest 24 h-tHB) to the 1st quartile group.Trends in 24 h-tHB
Trends in annual average 24 h-tHB in the 4 groups during
the follow-up period are shown in Fig. 2. In the 4th quartile
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Table 1
Baseline characteristics.
1st quartile,
63,036–100,264
N = 63
2nd quartile,
100,824–113,128
N = 63
3rd quartile,
113,219–130,152
N = 63
4th quartile,
130,270–198,672
N = 63
p-Value
Age (years) 67 ± 10 65 ± 10 64 ± 11 61 ± 10 0.0012
Sex  (female) 25 (40%) 12 (19%) 15 (24%) 11 (18%) 0.016
History of hypertension 16 (25%) 15 (24%) 12 (19%) 11 (18%) NS
Diabetes mellitus 8 (5%) 1 (2%) 7 (11%) 4 (6%) NS
Dyslipidemia 3 (5%) 4 (6%) 2 (3%) 3 (5%) NS
Structural heart disease 33 (52%) 22 (35%) 21 (33%) 7 (11%) <0.0001
Valvular heart disease 28 (44%) 14 (22%) 12 (19%) 2 (3%) <0.0001
Dilated cardiomyopathy 0 4 (6%) 5 (8%) 2 (3%) NS
Hypertrophic cardiomyopathy 0 2 (3%) 0 0 NS
Old  myocardial infarction 4 (6%) 6 (10%) 7 (11%) 1 (2%) NS
Lone  AF 3 (5%) 10 (16%) 13 (21%) 20 (32%) 0.001
Previous cerebral infarction 1 (2%) 2 (3%) 2 (3%) 2 (3%) NS
24-h  Holter recordings
Average HR (beats/min) 62 ± 7 76 ± 12 85 ± 13 102 ± 11 <0.0001
Minimum HR (beats/min) 40 ± 10 39 ± 11 40 ± 8 41 ± 8 NS
Maximum HR (beats/min) 172± 33 166± 32 163± 71 174± 34 NS
Baseline HR rest (beats/min) 81 ± 26 97 ± 28 100 ± 34 109 ± 28 <0.0001
Left  ventricle Dd (mm) 49  ± 6 50 ± 8 50 ± 7 50 ± 7 NS
Left  ventricle EF (%) 65 ± 9 61 ± 15 56 ± 17 55 ± 13 <0.0001
Left  atrial size (mm) 53 ± 10 50 ± 11 48 ± 10 52 ± 67 NS
Rate-control medications-in use (%) 35 (56%) 32 (51%) 39 (62%) 36 (57%) NS
Data are presented as the mean value ± SD or number (%) of patients. AF, atrial ﬁbrillation; Dd, diastolic diameter; EF, ejection fraction; HR, heart rate; and N, number of
quartile patients. NS, non-signiﬁcant.
Table 2
Drugs used during the initial 2 years.
1st quartile 2nd quartile 3rd quartile 4th quartile All patient p-Value
Calcium-channel blocker 32(51%) 24(38%) 30(48%) 24(38%) 100(40%) NS
  blocker 7(11%) 11(17%) 17(27%) 22(35%) 57(23%) NS
Digoxin 30(48%) 20(32%) 26(41%) 28(44%) 104(41%) NS
Aspirin 22(35%) 29(46%) 26(41%) 35(55%) 112(44%) NS
ACE  inhibitor or ARB 20(32%) 21(33%) 18(29%) 7(11%) 66(26%) 0.019
Warfarin 34(54%) 24(38%) 23(36%) 22(35%) 103(41%) 0.002
D -conv
g
b
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eata are presented as number (%) of patients. NS, non-signiﬁcant; ACE, angiotensin
roup, average 24 h-tHB decreased from 147,204 to 119,476
eats per day, with a reduction of 27,728 beats during 4 years.
o obvious changes were observed in the other 3 quartile
roups.
ig. 2. Trends of annual average 24-h total heart beats (24 h-tHB) during 4 years
fter the initial enrollment separated by quartiles of 24 h-tHB. Variation was  the
argest in the 4th quartile (highest quartile). Bars at each year indicate the standard
rror.erting enzyme; and ARB, angiotensin receptor blocker.
Endpoints
Cardiac events occurred in 33 patients, and the incidence
increased from the 4th to 1st quartile group (Table 3). In these 33
patients, 7 underwent implantation of a pacemaker or ICD. One
patient underwent implantation of a pacemaker for bradycardia-
induced syncope without heart failure.
Fig. 3 shows the Kaplan–Meier event-free survival curves for
cardiac events, presented separately in the 4 quartile groups. The
cumulative incidence rates of cardiac events at 5 years were 23.9%,
12.2%, 19.4%, and 7.2% in the 1st, 2nd, 3rd and 4th quartile groups,
respectively (log-rank test, p = 0.0074).
Predictors of clinical outcome
Signiﬁcant univariate predictors (with p < 0.01), other than 24 h-
tHB, for the cardiac events were age, EF, and presence of structural
heart diseases (especially valvular heart disease). In multivari-
ate model, 24 h-tHB < 100,000 was independently associated with
the incidence of cardiac events with an adjusted hazard ratio
of 2.45 [95% conﬁdence interval (CI), 1.09–5.49; p = 0.03], along
with the presence of structural heart disease (hazard ratio, 9.81;
95% CI, 3.34–28.83; p = 0.0001) and EF (hazard ratio, 0.97; 95% CI,
0.94–0.99; p = 0.002). (Table 4, Model 1). However, when valvular
heart disease was  substituted for structural heart disease as a vari-
able in the Cox proportional hazard model, 24 h-tHB < 100,000 was
no longer independently associated with cardiac events (hazard
ratio, 2.00; 95% CI, 0.90–4.46; p = 0.09) (Table 4, Model 2).
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Table  3
Adverse events.
1st quartile 2nd quartile 3rd quartile 4th quartile All patients p-Value
Cardiac events 15(24%) 7(11%) 8(13%) 3(5%) 33(13%) 0.015
Hospitalization with heart failure 15(24%) 7(11%) 8(13%) 3(5%) 33(13%) 0.015
Cardiac death 1(2%) 0 3(5%) 0 42(%) NS
Other  adverse events
Implantation of PM or ICD 6(10%) 1(2%) 0 1(2%) 8(3%) 0.010
Ventricular tachycardia 1(2%) 0 2(3%) 2(3%) 5(2%) NS
Hospitalization with AP or ACS 3(5%) 5(8%) 5(8%) 4(6%) 17(7%) NS
Stroke or TIA 4(6%) 1(2%) 3(5%) 2(3%) 10(4%) NS
All-cause mortality 4(6%) 0 6(10%) 1(2%) 11(4%) NS
Data are presented as number (%) of patients. NS, non-signiﬁcant; PM,  pacemaker; ICD
syndrome; and TIA, transient cerebral ischemic attack.
Fig. 3. Kaplan–Meier estimates for cumulative event-free survival rates of cardiac
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(11%/2 years), and the change in average 24 h-tHB was  near zero
over 4 years. Therefore, we cannot rule out the possibility that lower
T
R
2vents separated by 4 quartiles of 24-h total heart beats.
iscussion
The major ﬁnding of the present study was that low, but
ot high, 24 h-tHB was signiﬁcantly associated with increased
ikelihood of cardiac events (cardiac death and incidence of hos-
italization with heart failure). However, the effect of initial
4 h-tHB < 100,000 beats on cardiac events was abolished when
djusted by valvular heart disease, indicating confounding linking
etween low 24 h-tHB and valvular heart disease.
In our study, there was no evidence that higher rates led to
orse outcomes. The ﬁnding seems to be consistent with the recent
ACE II study, which indicated that lenient rate control was not
ssociated with more cardiovascular mortality and morbidity (pri-
ary outcome occurred 4.3%/year) [12]. Instead, unexpectedly, our
able 4
isk factors for cardiac events according to variables, comparing 2 models.
Hazard ratio 
Model 1a
24 h-tHB < 100,000 beats/day 2.45 
Age  1.04 
EF  (%) 0.96 
Presence of structural heart disease 6.09 
Model  2b
24 h-tHB < 100,000 beats/day 2.00 
Age  1.05 
EF  (%) 0.96 
Presence of valvular heart disease 10.23 
4 h-tHB, 24-h total heart beats; EF, ejection fraction.
a Calculated 24 h-tHB from a Cox proportional hazards regression analysis included 24
b Calculated 24 h-tHB from a Cox proportional hazards regression analysis included 24, implantable cardiovertor deﬁbrillator; AP, angina pectoris; ACS, acute coronary
ﬁndings suggest that a low heart rate is associated with a worse
clinical outcome.
However, the heart rate might be a marker for other causes of
morbidity. Presence of an echocardiographic structural heart dis-
ease is well known to be the most important factor for developing
heart failure. In the present study, patients with low heart rate had
more structural heart disease, which might be a signiﬁcant con-
founding factor. Actually, in our data, valvular heart disease seemed
to be strongly associated with low heart rate, because the associa-
tion between 24 h-tHB and cardiac events was independent when
adjusted by structural heart disease, but not independent when
adjusted by valvular heart disease.
The correlation between achieved heart rates and treatment
in our study is similar to that observed in previous analyses. All
patients in our study fulﬁlled the strict or lenient rate control crite-
ria of the RACE II study, resting heart rate <80 and <110 beats/min,
respectively [12]. RACE II is the ﬁrst moderate-sized random-
ized controlled trial that prospectively compared these strict and
lenient control groups. In RACE II, the average achieved heart rates
over the 3-year duration were approximately 75 (strict) and 85
(lenient) beats/min. In our study, after rates are converted from per
day (24 h) to per minute (/min), average heart rates at baseline
in the 4 quartiles were 62, 74, 83, and 102 beats/min, respec-
tively, and at 4 years after enrollment, the rates were 62, 73,
80, and 82 beats/min, respectively. Thus, our result seems con-
sistent with RACE II with respect to the mean achieved heart
rate.
During the follow-up period, patients in the high heart rate
group (2nd, 3rd, and 4th quartile) were less frequently treated
with beta-blockers (26%/2 years) than in the RACE II study
(66.6%/3 years), but reached <90 beats/min over a similar time
course. In the 1st quartile, beta-blockers were used less frequentlyusage of beta-blockers in the 1st quartile group is associated with
worse outcome.
95% CI p-Value
1.09–5.49 0.030
1.00–1.09 0.050
0.94–0.99 0.002
2.41–15.42 <0.0001
0.90–4.46 0.090
1.01–1.10 0.029
0.93–0.98 <0.0001
4.23–24.71 <0.0001
 h-tHB < 100,000, age, EF, and presence of structural heart disease.
 h-tHB < 100,000, age, EF, and presence of valvular heart disease.
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Relation of heart rate at rest and long-term (>20 years) death rate in initially6 K. Hirano et al. / Journal 
In addition, it should be noted that the lower limit in the
eart rate was not discussed in the previous AFFIRM [1] or
ACE II [12] studies. In our study, a signiﬁcant proportion of
he AF patients (about one-fourth) exhibited a low heart rate
f 24 h-tHB < 100,000 beats/day (63,036–100,264 beats/day). How-
ver, patients such as these, showing an average heart rate of
70 beats/min, were excluded from the RACE II study. Our main
esult came from the analysis of these excluded patients and sug-
ests that a low heart rate should be carefully considered in AF
atients.
Current opinion regarding recent rate control strategies in
atients with AF is that rapid ventricular response should be
ontrolled in order to mitigate symptoms, improve exercise capac-
ty, and increase cardiac function [14,15]. Typically, physicians
ndeavor to adjust the heart rate to that similar in healthy people
ith sinus rhythm [16]. A previous study of sinus rhythm patients
as shown that a resting heart rate of >75 beats/min was  associated
ith 1.9 times higher mortality compared with that of patients with
 resting heart rate of <60 beats/min [17]. To date, a higher heart
ate has been considered to be associated with worse clinical out-
ome in AF and, in contrast, a lower heart rate has not attracted
uch attention. Optimal heart rate control may  differ between
inus rhythm and AF.
tudy limitations
Our study should be interpreted in the context of limitations
mposed by an observational study design. It was theoretically pos-
ible for bias to exist in the adjudication process. The number of
atients with AF and the events for each endpoint were relatively
mall, thus limiting the power to assess predictors of prognosis.
oreover, selection bias might be present in this single hospital-
ased series; patients with lower rates might visit the hospital
ore often than those with high rates. Drugs were chosen freely
y attending physicians. These confounding factors suggest the
ossibility that rate is only a surrogate marker. Nevertheless, we
elieve that our ﬁndings provide a motivation for reconsidering
he unrecognized problems of rate control for AF.
onclusions
Our ﬁndings indicate a paradoxical hypothesis that low 24 h-
HB, but not high heart rate, correlates with subsequent heart
ailure in patients with permanent AF during rate control. Further
ffects of HR in AF should be targeted for detailed analysis in future
rospective studies.
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